Blog | BioInformant

Congress Moves to Reauthorize Funding for National Cord Blood and Bone Marrow Transplant Programs

September 11, 2025 By BioInformant Team Leave a Comment

Legislation would authorize $280 million over 5 years to support National Cord Blood and Bone Marrow Transplant Programs.

A bipartisan group of lawmakers in the U.S. House has introduced new legislation to extend funding for two cornerstone programs that connect patients with life-saving stem cell treatments. The Stem Cell Therapeutic and Research Reauthorization Act of 2025 proposes more than $280 million in federal funding over the next five years, ensuring that these initiatives continue past their current 2026 expiration date. [Read more…]

Can We Extend the Human Lifespan With Regenerative Medicine?

September 11, 2025 By Cade Hildreth, Founder & President 3 Comments

Regenerative medicine is a fascinating topic, because it requires you to ask yourself: Would you want to live to be 200 years old? A scientist from Stanford University thinks that it’s possible – so much so that he has placed a bet that there is someone alive today who will live to be 200 years old.

Over recent decades, modern scientific developments have led to a dramatic increase in human lifespan. But how much further can we go? Does regenerative medicine have the power to enable us all to live for many more years?

Let’s dive into this fascinating topic and find out more about regenerative medicine. How could it extend human life into the future? [Read more…]

Current and Future Opportunities for Stem Cell Exosomes

September 11, 2025 By Cade Hildreth, Founder & President Leave a Comment

To operate successfully within the exosome marketplace, it is vital to assess novel opportunities for product development. Currently, there are five market segments that compose the market for stem cell exosomes. These market segments include: Exosome therapeutics, diagnostic tools, research tools, cosmeceuticals, and manufacturing technologies. [Read more…]

Market Forces Affecting the Cord Blood and Cord Tissue Industry

September 9, 2025 By Cade Hildreth, Founder & President Leave a Comment

Recently released, the “Global Cord Blood & Tissue Banking Industry Report – Market Size, Segmentation, and Forecasts” explores clinical trial market data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue. Within this rapidly evolving marketplace, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.

Because the global cord blood banking industry has matured substantially over the past few years, new market forces have created both serious threats and novel opportunities. [Read more…]

Regenerelle® Issues Response to FDA Untitled Letter

September 9, 2025 By BioInformant Team Leave a Comment

Rochester, NY — September 8, 2025 — Regenerelle®, a global leader in the manufacturing and distribution of Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) and exosomes derived from WJ-MSCs, today announced the public release of its full response to the U.S. Food and Drug Administration (FDA) Untitled Letter dated May 22, 2023.

The disclosure is being made by AT Venture Center, the parent company of Regenerelle, LLC, the regenerative biotherapeutic manufacturing and distribution arm of the company providing stem cells and exosome products to its subsidiaries and distributors serving an extensive connected network of more than 4,000 regenerative medicine and aesthetics professionals worldwide, including MedSpas, orthopedic and pain clinics, wound care centers, and aesthetic practices. [Read more…]